Rhythm Pharmaceuticals Unveils Promising Phase 3 Trial Results for Setmelanotide in Treating Acquired Hypothalamic Obesity at ENDO 2025
Reuters
Jul 13
Rhythm Pharmaceuticals Unveils Promising Phase 3 Trial Results for Setmelanotide in Treating Acquired Hypothalamic Obesity at ENDO 2025
Rhythm Pharmaceuticals Inc. has announced new data from their clinical programs for acquired hypothalamic obesity, which were presented at the Endocrine Society's Annual Meeting (ENDO 2025) in San Francisco, CA. The presentations highlighted significant findings from the Phase 3 TRANSCEND trial, evaluating the efficacy of the MC4R agonists setmelanotide and bivamelagon. The data demonstrated clinically meaningful reductions in BMI for patients treated with these drugs. Specifically, setmelanotide showed a 19.8% placebo-adjusted difference in BMI reduction, with consistent results across various age and sex subgroups. Bivamelagon also showed promising results, with BMI reductions of up to 9.3% in specific dosage cohorts. These findings suggest potential therapeutic benefits for patients with acquired hypothalamic obesity. The full presentations from the ENDO 2025 conference are available on Rhythm Pharmaceuticals' website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9493287-en) on July 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.